RxDoctor Payments Data

Min Kim

Physician Assistant · Tualatin, ORNPI 1447708714

Payments from drug & device makers

$414in general payments, 2019–2025

Across 15 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$166
  • Novartis$73
  • Boston Scientific$43
  • Boehringer Ingelheim$33
  • E.r. Squibb & Sons, L.L.C.$33
  • Bridgebio Pharma, Inc.$18
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414 in reported general payments places this provider in the 70th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$39,362
Medicare patients
244
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$300,588
EntrestoSacubitril/Valsartan108$127,788
Repatha SureclickEvolocumab81$80,658
JardianceEmpagliflozin79$79,644
FarxigaDapagliflozin Propanediol76$52,873
MultaqDronedarone Hcl14$20,008
XareltoRivaroxaban13$17,748
BrilintaTicagrelor18$8,319
Metoprolol Succinate574$7,940
Potassium Chloride302$6,929
Ranolazine ErRanolazine36$5,132
Torsemide215$4,704
Atorvastatin Calcium264$3,241
Dofetilide19$2,927
Rosuvastatin Calcium118$2,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$300,588309 claims
NovartisEntresto$73$127,788108 claims
Boehringer IngelheimJardiance$33$79,64479 claims
AstraZenecaFarxiga, Brilinta$166$61,19294 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Tualatin

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →